The impact of pre-onset cannabis use on age at onset of prodromal and psychotic symptoms

Primary Psychiatry

Volumn 16, Issue 4, 2009, Pages 35-43

  Compton, Michael T ^a   Ramsay, Claire E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL STRESS; HUMAN; MENTAL DISEASE; ONSET AGE; PARANOID PSYCHOSIS; PATIENT ASSESSMENT; PROGNOSIS; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SYMPTOM;

EID: 76749102404     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Keshavan MS, Gilbert AR, Diwadkar VA. Neurodevelopmental theories. In: Lieberman JA, Stroup TS, Perkins DO, eds. Textbook of Schizophrenia. Washington, DC: American Psychiatric Publishing, Inc.; 2006:69-83.
2. Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004;363(9426):2063- 2072.
3. Walker EF. Developmentally moderated expressions of the neuropathology underlying schizophrenia. Schizophr Bull. 1994;20(3):453-480.
4. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997;104(4):667-685.
5. Andréasson S, Allebeck P, Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr Scand. 1989;79(5):505-510.
6. Arsenault L, Cannon M, Witton J, Murray R. Cannabis as a potential causal factor in schizophrenia. In: Castle DJ, Murray R, eds. Marijuana and Madness. Cambridge, MA: Cambridge University Press; 2004:101-118.
7. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol. 2005;19(2):187-194.
8. Smit F, Boiler L, Cuijpers P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004;99(4):425-430.
9. Weiser M, Noy S. Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci. 2005;7(1):81-85.
10. Zammit S, Allebeck P, Andréasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199-1203.
11. Substance Abuse and Mental Health Services Administration (SAMHSA). Office of Applied Studies. 2006 National Survey on Drug Use and Health: Detailed Tables. Available at: http://oas.samhsa.gov/NSDUH/ 2k6NSDUH/tabs/ Sect1peTabs1to46.htm#Tab1.19B. Accessed February 20, 2009.
12. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2004 National Survey on Drug Use and Health: National Findings. NSDUH Series H-25. DHHS Pub. No. 04-3964. Rockville, MD: SAMHSA; 2005.
13. National Institute on Drug Abuse (NIDA). InfoFacts. Marijuana. Available at: www.drugabuse.gov/PDF/ InfoFacts/Marijuana06.pdf. Accessed February 20, 2009.
14. Anthony JC, Petronis KR. Early-onset drug use and risk of later drug problems. Drug Alcohol Depend. 1995;40(1):9-15.
15. Compton WT, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. 2004;291(17):2114-2121.
16. Grant BF, Dawson DA. Age at onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 1998;10(2):163-173.
17. Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427-433.
18. Robins LN, Regier DA. Psychiatric Disorders in America. New York, NY: Free Press; 1991.
19. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry. 1994;51(1):8-19.
20. Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment Episode Data Set (TEDS). Highlights - 2003. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-27, DHHS Publication No. (SMA 05-4043). Rockville, MD: SAMHSA; 2005.
21. Compton MT, Goulding SM, Walker EF. Cannabis use, first-episode psychosis, and schizotypy: a summary and synthesis of recent literature. Cur Psychiatry Rev. 2007;3(3):161-171.
22. Hall WD. Cannabis use and the mental health of young people. Austr N Z J Psychiatry. 2006;40(2):105-113.
23. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178(2):101-106.
24. Mueser KT, Yarnold PR, Levinson DF, et al. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates. Schizophr Bull. 1990;16(1):31-56.
25. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-2518.
26. Bersani G, Orlandi V, Kotzalidis GD, Pancheri P. Cannabis and schizophrenia: impact on onset, course, psychopathology and outcomes. Eur Arch Psychiatry Clin Neurosci. 2002;252(2):86-92.
27. Dubertret C, Bidard I, Adès J, Gorwood P. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction. Schizophr Res. 2006;86(1-3):284-290.
28. Hambrecht M, Häfner H. Substance abuse and the onset of schizophrenia. Biol Psychiatry. 1996;40(11):1155-1163.
29. Hides L, Dawe S, Kavanagh DJ, Young RM. Psychotic symptom and cannabis relapse in recent-onset psychosis. Br J Psychiatry. 2006;189(2):137-143.
30. Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent onset schizophrenic disorders. Arch Gen Psychiatry. 1994;51(4):273-279.
31. Sevy S, Robinson DG, Holloway S, et al. Correlates of substance abuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr Scand. 2001;104(5):367-374.
32. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br J Psychiatry. 2005;187(4):306-313.
33. Addington J, Addington D. Impact of an early psychosis program on substance use. Psychiatr Rehab J. 2001;25(1):60-68.
34. Barnes TR, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188(3):237-242.
35. Compton MT, Furman AC, Kaslow NJ. Lower negative symptom scores among cannabis-dependent patients with schizophrenia-spectrum disorders: preliminary evidence from an African American first-episode sample. Schizophr Res. 2004;71(1):61-64.
36. Cantwell R, Brewin J, Glazebrook C, et al. Prevalence of substance misuse in first-episode psychosis. Br J Psychiatry. 1999;174(2):150-153.
37. Hambrecht M, Häfner, H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Austr N Z J Psychiatry. 2000;34(3):468-475.
38. Rabinowitz J, Bromet EJ, Lavelle J, Carlson G, Kovasznay B, Schwartz JE. Prevalence and severity of substance use disorder and onset of psychosis in first-admission psychotic patients. Psychol Med. 1998;28(6):1411-1419.
39. Wade D, Harrigan S, McGorry PD, Burgess PM, Whelan G. Impact of severity of substance use disorder on symptomatic and functional outcome in young individuals with first-episode psychosis. J Clin Psychiatry. 2007;68(5):767-774.
40. Silver H, Abboud E. Drug abuse in schizophrenia: comparison of patients who began drug abuse before their first admission with those who began abusing drugs after their first admission. Schizophr Res. 1994;13(1):57-63.
41. Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res. 2002;54(3):243-251.
42. Mauri M, Volonteri L, De Gaspari I, Colasanti A, Brambilla M, Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health. 2006;2:4-12.
43. Veen ND, Selten JP, van der Tweel I, Feller WG, Hoek HW, Kahn RS. Cannabis use and age at onset of schizophrenia. Am J Psychiatry. 2004;161(3):501-506.
44. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988;34(5):605-613.
45. Iversen L. Cannabis and the brain. Brain. 2003;126(6):1252-1270.
46. Zammit S, Lewis G. Exploring the relationship between cannabis use and psychosis. Addiction. 2004;98(11):1353-1355.
47. Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neurosci. 2001;103(1): 9-15.
48. Sundram S, Dean B, Copolov D. The endogenous cannabinoid system in schizophrenia. In: Castle DJ, Murray R, eds. Marijuana and Madness. Cambridge, MA: Cambridge University Press; 2004:127-141.
49. Zavitsanou K, Garrick T, Huang XF. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress Neuro-Psychopharmacol Biol Psychiatry. 2004;28(2):355-360.
50. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2(5):5-14.
51. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29(11):2108-2114.
52. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665-1669.
53. Leroy S, Griffon N, Bourdel MC, Olié JP, Poirier MF, Krebs MO. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet (Neuropsychiatr Genet). 2001;105(8):749-752.
54. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry. 2002;7(5):515-518.
55. Zammit S, Spurlock G, Williams H, Norton N, Williams N, O'Donovan M, Owen MJ. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br J Psychiatry. 2007;191(5):402-407.
56. Allen NC, Bagade S, McQueen MB, et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet. 2008;40(7):827-834.
57. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608.
58. Johnstone EC, Owens DG, Bydder GM, Colter N, Crow TJ, Frith CD. The spectrum of structural brain changes in schizophrenia: age at onset as a predictor of cognitive and clinical impairments and their cerebral correlates. Psycholog Med. 1989;19(1):91-103.
59. Mayer C, Kelterborn G, Naber D. Age at onset in schizophrenia: relations to psychopathology and gender. Br J Psychiatry. 1993;162(5):665-671.
60. Häfner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1995;245(2):80-92.
61. Sharma RP, Dowd SM, Davis JM, Janicak PG. Age of illness onset and schizophrenic symptomatology during an inpatient washout period. Schizophr Res. 1996;20(3):295-300.
62. Jeste DV, McAdams LA, Palmer BW, et al. Relationship of neuropsychological and MRI measures to age at onset of schizophrenia. Acta Psychiatr Scand. 1998;98(2):156-164.
63. Banaschewski T, Schulz E, Martin M, Remschmidt H. Cognitive functions and psychopathological symptoms in early-onset schizophrenia. Eur Child Adolesc Psychiatry. 2000;9(1):11-20.
64. Lay B, Blanz B, Hartmann M, Schmidt MH. The psychosocial outcome of adolescent-onset schizophrenia: a 12-year followup. Schizophr Bull. 2000;26(4):801-816.
65. Tuulio-Henriksson A, Partonen T, Suvisaari J, Haukka J, Lonnqvist J. Age at onset and cognitive functioning in schizophrenia. Br J Psychiatry. 2004;185(3):215-219.
66. Rhinewine JP, Lencz T, Thaden EP, et al. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry. 2005;58(9):705-712.
67. Ropcke B, Eggers C. Early-onset schizophrenia: a 15-year follow-up. Eur Child Adolesc Psychiatry. 2005;14(6):341-350.
68. Amminger GP, Leicester S, Yung AR, et al. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res. 2006;84(1):67-76.
69. Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006;36(5):649-658.
70. Van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):69-72.
71. González-Pinto A, Vega P, Ibáñez B, et al. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry. 2008;69(8):1210-1216.
72. Corcoran CM, Kimhy D, Stanford A, et al. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res. 2008;106(2-3):286-293.
73. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes. Lancet. 2007;370(9584):319-328.
74. Ferdinand RF, Sondeijker F, van der Ende J, Selten JP, Huizink A, Verhulst FC. Cannabis use predicts future psychotic symptoms, and vice versa. Addiction. 2005;100(5):612-618.
75. Verdoux H, Tournier M, Cougnard A. Impact of substance use on the onset and course of early psychosis. Schizophr Res. 2005;79(1):69-75.
76. Bodkin L, Singh A, Corcoran C. Cannabis as a risk factor for psychosis in vulnerable teens: implications for treatment. Primary Psychiatry. 2008;15(6):51-57.
77. Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend. 2001;64(3):319-327.
78. Grant BF, Hansan DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States. Arch Gen Psychiatry. 2004;61(11):1107-1115.
79. Hunglund BL, Basavarajappa BS. Are anandamide and cannabinoid receptors involved in ethanol tolerance? A review of the evidence. Alcohol Alcohol. 2000;35(2):126-133.
80. Poirier MF, Canceil O, Bayle F, et al. Prevalence of smoking in psychiatric patients. Progress Neuropsychopharmacol Biol Psychiatry. 2002;26(3):529-537.
81. Üçok A, Polat A, Bozkurt O, Meteris H. Cigarette smoking among patients with schizophrenia and bipolar disorders. Psychiatry Clin Neurosci. 2004;58(4):434-437.
82. Weiser M, Reichenberg A, Grotto I, et al. Higher rates of cigarette smoking in male adolescents before the onset of schizophrenia: a historical-prospective cohort study. Am J Psychiatry. 2004;161(7):1219-1223.
83. Sacco KA, Termine A, Seyal A, et al. Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry. 2005;62(6):649-659.
84. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2(1):19-37.
85. Ziedonis DM, George TP. Schizophrenia and nicotine use: Report of pilot smoking cessation programs and review of neurobiological and clinical issues. Schizophr Bull. 1997;23(2):247-254.
86. Miettunen J, Törmänen S, Murray GK, et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry. 2006;192(6):140-141.
87. Angermeyer MC, Kühn L. Gender differences in age at onset of schizophrenia: an overview. Eur Arch Psychiatry Neurol Sci. 1988;237(6):351-364.
88. DeLisi LE. The significance of age at onset for schizophrenia. Schizophr Bull. 1992;18(2):209-215.
89. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3-38.
90. Häfner H, Maurer K, Löffler W, Reicher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993;162(1):80-86.
91. Häfner H, Maurer K, Löffler W, et al. The ABC Schizophrenia Study: a preliminary overview of the results. Soc Psychiatry Psychiatr Epidemiol. 1998;33(8):380-386.
92. Shimizu A, Kurachi M, Yamaguchi N, Torii H, Isaki K. Does family history of schizophrenia influence age at onset of schizophrenia? Acta Psychiatr Scand. 1988;78(6):716-719.
93. Gorwood P, Leboyer M, Jay M, Payan C, Feingold J. Gender and age at onset in schizophrenia: impact of family history. Am J Psychiatry. 1995;152(1):208-212.
94. Stompe T, Ortwein-Swoboda G, Strobl R, Friedmann A. The age at onset of schizophrenia and the theory of anticipation. Psychiatry Res. 2000;93(2):125-134.